Working… Menu
Trial record 4 of 7 for:    Prevail AND delivery system

Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (JAPAN) (PREVAIL JAPAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01113983
Recruitment Status : Unknown
Verified February 2014 by Edwards Lifesciences.
Recruitment status was:  Active, not recruiting
First Posted : April 30, 2010
Last Update Posted : February 21, 2014
Information provided by (Responsible Party):
Edwards Lifesciences

Brief Summary:
A single arm, prospective multicenter non-randomized pivotal clinical trial evaluating the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX), NovaFlex™ transfemoral delivery system, Ascendra2™ transapical delivery system and crimper accessories. The trial includes a premarket pivotal cohort to evaluate the system performance as well as a post market clinical follow-up phase involving long term follow-up of all patients to evaluate the safety of investigational devices up to 5 years.

Condition or disease Intervention/treatment Phase
Aortic Valve Stenosis Efficacy Endpoints Improvement of Aortic Valve Area and NYHA Functional Classification Drug: Transcatheter aortic valve implantation Not Applicable

Detailed Description:

Purpose: To evaluate the safety and efficacy of THV-9300 for patients who have severe symptomatic aortic stenosis attributed to calcification and degeneration of a valve leaflet and for whom undergoing a surgery safely would be difficult.

Enrollment: 69 patients Transfemoral approach: 42 patients (No. of patients needed: 23) Transapical approach: 27 patients (No. of patients needed: 19)

Follow-up: Subject data collection will include clinical information at baseline and during the index procedure. Subjects will undergo clinical follow-up at discharge, 30 days, 6 months and annually for 5 years.

Clinical sites: Osaka University Hospital Kurashiki Central Hospital Sakakibara Heart Institute

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Trial of a Transcatheter Bioprosthetic Valve for Patients With Aortic Stenosis
Study Start Date : April 2010
Actual Primary Completion Date : October 2011
Estimated Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Transcatheter aortic valve implantation
    Transcatheter aortic valve implantation via transfemoral or transapical approach
    Other Names:
    • NovaFlex delivery system
    • Ascendra2 delivery system

Primary Outcome Measures :
  1. improvement in Aortic valve area (AVA) and NYHA functional classification [ Time Frame: 6 Months ]
    improvement in Aortic valve area (AVA) and NYHA functional classification

Secondary Outcome Measures :
  1. Adverse Event Rate [ Time Frame: 5 Years ]
    Adverse Event Rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary:

Patients who were judged difficult to safely undergo AVR Severe senile degenerative aortic valve stenosis NYHA Functional Class II or greater Signed Informed Consent

Exclusion Criteria:

  • Primary:

Aortic valve is congenital unicuspid or bicuspid Annulus size between < 18 mm or > 25 mm LVEF < 20 %

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01113983

Layout table for location information
Kurashiki Central Hospital
Kurashiki, Okayama, Japan, 710-8602
Osaka University Hospital
Suita, Osaka, Japan, 565-0871
Sakakibara Heart Institute
Chofu, Tokyo, Japan, 183-0003
Sponsors and Collaborators
Edwards Lifesciences

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Edwards Lifesciences Identifier: NCT01113983     History of Changes
Other Study ID Numbers: EW-P-001
First Posted: April 30, 2010    Key Record Dates
Last Update Posted: February 21, 2014
Last Verified: February 2014
Keywords provided by Edwards Lifesciences:
SAPIEN XT Valve, Cardiovascular Disease, Valvular Heart Disease, Aortic Stenosis, Heart Valve Therapy, Transapical, Transcatheter, Transfemoral
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Constriction, Pathologic
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction